  0 Table of Contents |
  1 Home |
| 2 Background |
 3 Artifacts Summary |
 3.1 ICR Administrative Coverage Measure |
| 3.2 ICR Campaign Readiness Measure |
| 3.3 ICR Geographic Coverage Measure |
| 3.4 ICR MDA Treatment Coverage Measure |
| 3.5 ICR Survey Coverage Measure |
| 3.6 ICR Zero-dose Coverage Measure |
| 3.7 ICR Campaign Readiness Checklist |
| 3.8 ICR MDA Supervision Checklist |
| 3.9 ICR Administrative Coverage |
| 3.10 ICR Adverse Event |
| 3.11 ICR Campaign |
| 3.12 ICR Campaign Activity |
| 3.13 ICR Campaign Form Response |
| 3.14 ICR Campaign Protocol |
| 3.15 ICR Campaign Task |
| 3.16 ICR Care Team |
| 3.17 ICR Consent (Person-Data Governance) |
| 3.18 ICR Delivery Unit (Household / Community / School Cohort) |
| 3.19 ICR Facility Organization |
| 3.20 ICR Immunization Event |
| 3.21 ICR Location |
| 3.22 ICR Location Status |
| 3.23 ICR Medication Administration |
| 3.24 ICR Patient (Beneficiary / Registered Individual) |
| 3.25 ICR Supply Distribution |
| 3.26 ICR Supply Movement |
| 3.27 ICR Survey Coverage |
| 3.28 ICR Target Population |
| 3.29 Campaign |
| 3.30 Campaign Round |
| 3.31 Coverage Source |
| 3.32 Coverage Unit |
| 3.33 Delivery Strategy |
| 3.34 Denominator Source |
| 3.35 Denominator Type |
| 3.36 Directly Observed Consumption |
| 3.37 Distribution Recipient |
| 3.38 Dose-pole Band |
| 3.39 Estimate Confidence |
| 3.40 Estimate Date |
| 3.41 Group Location |
| 3.42 Is Calculated |
| 3.43 Is Planning Denominator |
| 3.44 Issued To Team |
| 3.45 Location Boundary (GeoJSON) |
| 3.46 Oversees Area |
| 3.47 Planning Denominator |
| 3.48 Prior-dose Status (Zero-dose) |
| 3.49 Real-time vs Reconciled |
| 3.50 Record Origin |
| 3.51 Reporter Team |
| 3.52 Sample Design |
| 3.53 Serious-Event Criteria |
| 3.54 Settlement / Special-population Type |
| 3.55 Social Mobilization |
| 3.56 Stock Accountability |
| 3.57 Target Geography |
| 3.58 Task Origin |
| 3.59 Workload Target |
| 3.60 ICR Adverse Event Causality |
| 3.61 ICR Adverse Event Seriousness |
| 3.62 ICR Campaign Type |
| 3.63 ICR Communication Channel |
| 3.64 ICR Coverage Source |
| 3.65 ICR Coverage Stratifier |
| 3.66 ICR Coverage Unit |
| 3.67 ICR Data Lineage |
| 3.68 ICR Delivery Strategy |
| 3.69 ICR Denominator Source |
| 3.70 ICR Denominator Type |
| 3.71 ICR Dose History / Zero-dose Status |
| 3.72 ICR Endemicity Status |
| 3.73 ICR Exclusion Reason |
| 3.74 ICR Facility Ownership |
| 3.75 ICR Facility Type |
| 3.76 ICR Group Kind |
| 3.77 ICR Independent Coverage Source |
| 3.78 ICR Location Status |
| 3.79 ICR Location Type |
| 3.80 ICR MDA Medication |
| 3.81 ICR MDA Medicine Package |
| 3.82 ICR Missed Reason |
| 3.83 ICR NTD Disease |
| 3.84 ICR Record Origin |
| 3.85 ICR Refusal Reason |
| 3.86 ICR Revisit Outcome |
| 3.87 ICR Serious-Event Criteria |
| 3.88 ICR Settlement / Special-population Type |
| 3.89 ICR Supplied Item |
| 3.90 ICR Task Origin |
| 3.91 ICR Task Output Type |
| 3.92 ICR Team Role |
| 3.93 ICR Adverse Event Causality |
| 3.94 ICR Campaign Type |
| 3.95 ICR Commodity Class |
| 3.96 ICR Communication Channel |
| 3.97 ICR Coverage Source |
| 3.98 ICR Coverage Stratifier |
| 3.99 ICR Coverage Unit |
| 3.100 ICR Data Lineage |
| 3.101 ICR Delivery Strategy |
| 3.102 ICR Denominator Source |
| 3.103 ICR Denominator Type |
| 3.104 ICR Dose History / Zero-dose Status |
| 3.105 ICR Endemicity Status |
| 3.106 ICR Exclusion Reason |
| 3.107 ICR Facility Ownership |
| 3.108 ICR Facility Type |
| 3.109 ICR Group Characteristic |
| 3.110 ICR Group Kind |
| 3.111 ICR Location Status |
| 3.112 ICR Location Type |
| 3.113 ICR MDA Medicine Package |
| 3.114 ICR Missed Reason |
| 3.115 ICR NTD Disease |
| 3.116 ICR Project Tag |
| 3.117 ICR Record Origin |
| 3.118 ICR Refusal Reason |
| 3.119 ICR Revisit Outcome |
| 3.120 ICR Serious-Event Criteria |
| 3.121 ICR Settlement / Special-population Type |
| 3.122 ICR Task Origin |
| 3.123 ICR Task Output Type |
| 3.124 ICR Team Role |
| 3.125 ICR ↔ WHO IMMZ AEFI Causality |
| 3.126 Administer albendazole — MDA activity definition |
| 3.127 Administer MCV — campaign activity definition |
| 3.128 Administrative coverage — Kambia MR SIA, June 2026 round |
| 3.129 Adverse event — abdominal pain following albendazole |
| 3.130 AEFI — anaphylaxis following MCV dose (serious) |
| 3.131 AEFI — fever following MCV dose |
| 3.132 Albendazole administration — MDA register entry |
| 3.133 Albendazole issue — CDD team 7, day 1 (field-team daily stock) |
| 3.134 Albendazole receipt — Rokupr community (ATC-coded drug supply) |
| 3.135 Campaign readiness roll-up — Kambia, pre-campaign validation |
| 3.136 Care team — CDD team 7, Rokupr |
| 3.137 Community-directed MDA — Rokupr, albendazole round |
| 3.138 Distribute ITNs — activity definition |
| 3.139 ESPEN MDA — 1. Location Registration Form |
| 3.140 ESPEN MDA — 2. Medicine Receipt Form |
| 3.141 ESPEN MDA — 3. Medicine Treatment Form (tally) |
| 3.142 ESPEN MDA — 4. Medicine Use & Case Management Form |
| 3.143 ESPEN MDA — 5. Supervision: Health Facility |
| 3.144 ESPEN MDA — 6. Supervision: CDD Observation |
| 3.145 Example Child |
| 3.146 Example Community — Rokupr |
| 3.147 Example Consent — registry data sharing |
| 3.148 Example Country |
| 3.149 Example District |
| 3.150 Example Dwelling |
| 3.151 Example Facility Organization — Rokupr CHC |
| 3.152 Example Facility — Rokupr CHC (place) |
| 3.153 Example Fixed Post — Rokupr CHC |
| 3.154 Example Head of Household |
| 3.155 Example Household |
| 3.156 Example Household — fully enumerated |
| 3.157 Example School Cohort — Rokupr Primary School |
| 3.158 Example School — Rokupr Primary School |
| 3.159 Example Settlement |
| 3.160 Example Sibling |
| 3.161 Example Supervisory Area |
| 3.162 Example Target Population — at-risk population, Rokupr community (STH MDA) |
| 3.163 Example Target Population — children 9m–14y, Kambia District |
| 3.164 Example Target Population — children 9m–14y, Kambia District (enumeration estimate) |
| 3.165 Example Target Population — children 9m–14y, Kambia District (sum of ward microplan estimates, calculated) |
| 3.166 Example Target Population — children 9m–14y, Sierra Leone (national) |
| 3.167 Example Target Population — population protected, Rokupr IRS |
| 3.168 Example Target Population — school-aged children 5–14, Kambia District (descoped round) |
| 3.169 Example Ward — national DHIS2 code only |
| 3.170 Follow-up revisit — missed child, Rokupr block 4 |
| 3.171 Geographic coverage — Kambia MDA (villages treated / total) |
| 3.172 IRS protocol — annual indoor residual spraying |
| 3.173 IRS Rokupr — 2026 annual round |
| 3.174 IRS structure visit — Rokupr block 4, house 12 |
| 3.175 ITN distribution to household |
| 3.176 Kambia MR SIA — June 2026 round |
| 3.177 Kambia SCH MDA 2026 — descoped round (SAC only, supply-constrained) |
| 3.178 LF endemicity — Kambia District (endemic, under MDA) |
| 3.179 LQAS lot assessment — Kambia MR SIA, June 2026 round |
| 3.180 MCV dose — campaign record |
| 3.181 MDA treatment coverage — Rokupr albendazole round (sex × age stratified) |
| 3.182 Measles–Rubella SIA Protocol |
| 3.183 Mop-up household visit — Rokupr block 4, house 12 |
| 3.184 Onchocerciasis endemicity — Kambia District (non-endemic) |
| 3.185 Post-campaign survey coverage — Kambia MR SIA, June 2026 round |
| 3.186 Readiness validation — Kambia supervision zone 2 |
| 3.187 Schistosomiasis MDA protocol — national policy: everyone 2+ |
| 3.188 School session — praziquantel MDA at Rokupr Primary School |
| 3.189 Sierra Leone MR SIA 2026 — national umbrella campaign |
| 3.190 Site session — Rokupr CHC fixed post, campaign day 3 |
| 3.191 Spray structure — IRS activity definition |
| 3.192 STH MDA eligible population — school-age children 5–14 years (definitional) |
| 3.193 STH MDA protocol — albendazole, community-directed |
| 3.194 STH MDA, Rokupr community — February 2026 round |
| 3.195 Supervision report — CDD observation, Rokupr |
 3.196 Zero-dose reach — Kambia MR SIA, June 2026 round |
